Repligen to acquire BioLife

Repligen has agreed to acquire BioLife in a strategic acquisition completed on 6 October 2026. Both companies are based in the United States and operate within the healthcare sector. The transaction involved a combination of cash and shares as consideration, although the specific headline offer value was not reported in the available data. This deal represents a consolidation of assets between two US-based entities in the healthcare industry. The acquisition was announced and completed on the same day, indicating a swift execution process for this strategic move. No further details regarding the financial magnitude of the transaction were disclosed in the primary records. The structure of the deal, utilizing both cash and equity, suggests a balanced approach to the purchase price. The completion of this acquisition marks the formal integration of BioLife into Repligen’s portfolio. The transaction status is recorded as completed, with no pending regulatory hurdles noted in the final status update. This event is logged in the archive as a concluded strategic acquisition between two US healthcare firms. The lack of a reported deal value prevents any quantitative analysis of the purchase price relative to market standards. The primary focus remains on the structural and operational aspects of the merger.